Research
Hormonal
GLP-1 receptor agonists, specifically liraglutide, produce significant weight loss in obese patients with or without type 2 diabetes, representing a repositioning strategy for obesity treatment.
GLP-1 agonists like liraglutide help with weight loss by suppressing appetite. They are used in both diabetic and non-diabetic obese patients. The average weight loss is around 2.9 kg more than control groups in meta-analyses.
GoodSupportsHIGH confidence
the appetite-suppressant properties of such agents are being exploited in an approach to managing obesity even in patients without diabetes... showed a greater weight loss was achieved in patients treated with GLP-1R compared with control groups (weighted mean difference −2.9 kg...)
Why this rating
Based on a meta-analysis of 21 trials.
Source
Pharmacotherapy for obesity: novel agents and paradigms
Sean Manning et al. · Therapeutic Advances in Chronic Disease · 2014
DOI 10.1177/2040622314522848
narrative_reviewCited 92×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lorcaserin, a selective serotonin 2C receptor agonist, produces modest but clinically significant weight loss (mean 3.2-5.0 kg) compared to placebo, though tolerance may develop over two years of treatment.Good
- The combination of low-dose phentermine and extended-release topiramate produces significantly greater weight loss (up to 10.9%) than monotherapies or placebo, with a favorable benefit-risk profile regarding cardiovascular events despite increased heart rate.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →